-
<![CDATA[Beyond the Primary End Point: Diving Deeper into the EMERALD trial | Written Recap]]>
02 Nov 2025 00:25 GMT
… Mayo Clinic College of Medicine in Rochester, Minnesota … discontinue treatment.
EMERALD trial design
The EMERALD trial investigators … three aromatase inhibitors: anastrozole, letrozole or exemestane. … and partnerships with pharmaceutical partners with copay …
-
<![CDATA[Verzenio and Kisqali Deliver Positive Long-Term Results in Early Breast Cancer Trials]]>
20 Oct 2025 22:21 GMT
… FirstWord Pharma, some doctors have had reservations around … breast cancer medicine and consultant medical oncologist at The … trial (NCT03701334) of Kisqali (ribociclib) revealed that treatment … -steroidal aromatase inhibitor (anastrozole or letrozole) with …
-
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
20 Oct 2025 08:15 GMT
… 2025 European Society for Medical Oncology (ESMO) Congress … (ER) degrader, or anastrozole in postmenopausal ER+… S. Food and Drug Administration (FDA) has accepted the … treatment option. About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology …
-
Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
17 Oct 2025 12:28 GMT
… two-year treatment period in the monarchE trial, an … Verzenio plus anastrozole or letrozole vs anastrozole or letrozole, … the power of biotechnology, chemistry and genetic medicine, our scientists … , as with any pharmaceutical product, there are substantial …
-
‘9-1-1’ Actor Rockmond Dunbar Heads to Trial Over COVID Vaccine
14 Oct 2025 00:22 GMT
… is “not against western medicine that is made with … as injections of anastrozole, a chemotherapy drug intended to prevent … of Dunbar’s medical records at trial, arguing they were … irrelevant, but the judge disagreed.
“Dunbar’s medical …
-
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
13 Oct 2025 11:00 GMT
… the European Society for Medical Oncology (ESMO) … (ER) degrader, or anastrozole in postmenopausal ER+/ … FDA, supporting the potential for vepdegestrant to offer a meaningful new treatment … is a clinical-stage biotechnology company dedicated to improving …
-
Imlunestrant vs Elacestrant: MOA and Clinical Trial Differences
10 Oct 2025 22:47 GMT
… , FACP, a breast medical oncologist and early drug development specialist at Memorial … trials leading to each therapy’s approvals.
The phase 3 EMERALD trial … inhibitors: we have letrozole [Femara], anastrozole [Arimidex], and exemestane [Aromasin]. We …
-
<![CDATA[Selecting Second-Line Treatment in HR+, HER2-Low Breast Cancer]]>
07 Oct 2025 02:15 GMT
… , MD, professor of medicine and oncology, associate director … of adjuvant anastrozole
Three years after completing anastrozole, she …
ECOG performance status: 1
Treatment: letrozole (Femara) plus ribociclib … randomized phase III EMERALD trial. J Clin Oncol. …
-
Addressing Treatment Side Effects in Breast Cancer
29 Sep 2025 17:43 GMT
… randomized controlled trials, including … trial, a nonrandomized, multicenter study of patients who discontinued anastrozole … medication for CRF. Most pharmacologic treatments, such as certain antidepressants … treatments.
Duloxetine is the only pharmaceutical …
-
Roche's oral SERD comes good in 2nd-line breast cancer trial
23 Sep 2025 12:32 GMT
… as aromatase inhibitors like letrozole, anastrozole, or exemestane.
It… reporting disappointing clinical results.
One drug in the class – Menarini … in lidERA, with both trials due to read out … also looking at adjuvant treatment with camizestrant in the …
About
© 1995-2025